Amphastar Pharmaceuticals (AMPH) Assets (2013 - 2026)

Amphastar Pharmaceuticals has reported Assets for 14 years, with the latest figure at $1.7 billion in Q2 2026.

• On a quarterly basis, Assets rose 7.95% year-over-year to $1.7 billion in Q2 2026; TTM through Jun 2026 was $1.7 billion, a 7.95% increase from a year earlier, with the FY2025 full-year figure at $1.6 billion, up 3.29% from the prior year.
• Assets was $1.7 billion for Q2 2026 at Amphastar Pharmaceuticals, up from $1.6 billion in the prior quarter.
• The five-year high for Assets was $1.7 billion in Q2 2026, with the low at $716.2 million in Q1 2022.
• Average Assets over 5 years is $1.3 billion, with a median of $1.5 billion recorded in 2023.
• The sharpest annual moves came in 2023 and 2024: Assets jumped 112.56% in 2023, then advanced 0.04% in 2024.
• Over 5 years, Assets stood at $742.0 million in 2022, then surged by 103.9% to $1.5 billion in 2023, then rose by 4.27% to $1.6 billion in 2024, then climbed by 3.29% to $1.6 billion in 2025, then increased by 7.03% to $1.7 billion in 2026.
• The last three Assets figures came in at $1.7 billion (Q2 2026), $1.6 billion (Q1 2026), and $1.6 billion (Q4 2025), per Business Quant data.